Last reviewed · How we verify
Neurotox (CESIUM)
At a glance
| Generic name | CESIUM |
|---|---|
| Sponsor | BioActive Nutritional, Inc. |
| Drug class | Acetylcholine Release Inhibitor [EPC] |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Numbness relief
- Tingling relief
- Muscle cramps relief
- Nerve pain relief
Common side effects
Key clinical trials
- Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study (PHASE2)
- Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC (PHASE1,PHASE2)
- Feasibility Study of the Xoft® Axxent® Electronic Brachytherapy System for the Treatment of Cervical Cancer (NA)
- Intraoperative Placement of Cesium-131 Permanent Interstitial Brachytherapy in Head and Neck Cancer (EARLY_PHASE1)
- Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer (PHASE2)
- Docetaxel and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer (PHASE1,PHASE2)
- Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer (PHASE1,PHASE2)
- MBI and Breast Tomosynthesis Screening Accuracies in Patients With Dense Breast Tissue (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neurotox CI brief — competitive landscape report
- Neurotox updates RSS · CI watch RSS
- BioActive Nutritional, Inc. portfolio CI